WallStreetZenWallStreetZen

NASDAQ: ELVN
Enliven Therapeutics Inc Stock Ownership - Who owns Enliven Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Enliven Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Joseph P. LyssikatosCHIEF SCIENTIFIC OFFICER2026-01-205,491$26.37
$144.81kSell
Richard A. HeymanDirector2026-01-20512$26.46
$13.55kSell
Richard A. HeymanDirector2026-01-20718$26.96
$19.35kSell
Joseph P. LyssikatosCHIEF SCIENTIFIC OFFICER2026-01-2014,509$26.90
$390.28kSell
Joseph P. LyssikatosCHIEF SCIENTIFIC OFFICER2026-01-0950,000$29.13
$1.46MSell
Anish PatelCHIEF OPERATING OFFICER2026-01-09243$28.50
$6.93kSell
Joseph P. LyssikatosCHIEF SCIENTIFIC OFFICER2026-01-0941,198$24.90
$1.03MSell
Richard A. HeymanDirector2026-01-094,285$25.00
$107.13kSell
Anish PatelCHIEF OPERATING OFFICER2026-01-0948,057$27.98
$1.34MSell
Richard A. HeymanDirector2026-01-081,620$25.00
$40.50kSell

1 of 11

ELVN insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ELVN insiders and whales buy or sell their stock.

ELVN Shareholders

What type of owners hold Enliven Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Orbimed Advisors LLC17.18%10,195,751$261.72MInsider
David P. Bonita14.15%8,398,136$215.58MInsider
5am Partners VI LLC13.72%8,142,154$209.01MInsider
Orbimed Advisors LLC13.41%7,959,538$204.32MInstitution
Rishi Gupta13.40%7,951,463$204.11MInsider
Fmr LLC12.01%7,129,196$183.01MInstitution
Commodore Capital LP7.91%4,692,809$120.46MInstitution
Fairmount Funds Management LLC6.25%3,711,444$95.27MInstitution
Ra Capital Management LP6.03%3,576,813$91.82MInsider
Blackrock Inc5.93%3,518,524$90.32MInstitution

1 of 3

ELVN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ELVN49.58%50.42%Net SellingNet Selling
AMLX66.53%33.47%Net SellingNet Buying
TNGX62.73%37.27%Net Selling
FTRE99.48%0.52%Net Buying
PGEN27.27%72.73%Net SellingNet Selling
View Top Biotech Stocks

Enliven Therapeutics Stock Ownership FAQ

Who owns Enliven Therapeutics?

Enliven Therapeutics (NASDAQ: ELVN) is owned by 100.09% institutional shareholders, 101.78% Enliven Therapeutics insiders, and 0.00% retail investors. Orbimed Advisors LLC is the largest individual Enliven Therapeutics shareholder, owning 10.20M shares representing 17.18% of the company. Orbimed Advisors LLC's Enliven Therapeutics shares are currently valued at $269.68M.

If you're new to stock investing, here's how to buy Enliven Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.